Stocks News

LAST PRICE
0.4844
TODAY'S CHANGE (%)
Trending Down-0.0488 (-9.1523%)

Bid / Lots
0.4817/ 60
Ask / Lots
0.5100/ 10
Open / Previous Close
0.5300 / 0.5332
Day Range
Low 0.4444
High 0.5305
52 Week Range
Low 0.2020
High 1.8180
Volume
3,085,318
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Yesterday
- DJ Unicycive Therapeutics Price Target Maintained With a $2.50/Share by HC Wainwright & Co., from 18 hours ago by Dow Jones
  18 hours ago by Dow Jones
  Companies Mentioned: UNCY
  
  Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings
  
  (END) Dow Jones Newswires
  
  November 12, 2024 06:47 ET (11:47 GMT)
Nov 11, 2024
- Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate, from 7:47AM ET on Monday Nov 11, 2024 by MT Newswires
  7:47AM ET on Monday Nov 11, 2024 by MT Newswires
  Companies Mentioned: UNCY
  07:47 AM EST, 11/11/2024 (MT Newswires) -- Unicycive Therapeutics (UNCY) said Monday that the US Food and Drug Administration has accepted its new drug application for oxylanthanum carbonate, and has set a target action date set of June 28, 2025. Th...
- DJ Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia, from 7:31AM ET on Monday Nov 11, 2024 by Dow Jones
  7:31AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: UNCY
  
  By Colin Kellaher
  
  Unicycive Therapeutics said the Food and Drug Administration accepted its application seeking approval of its lead drug candidate as a treatment for an electrolyte disorder related to kidney disease.
- Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis, from 7:00AM ET on Monday Nov 11, 2024 by Dow Jones
  7:00AM ET on Monday Nov 11, 2024 by Dow Jones
  Companies Mentioned: UNCY
  
  Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis
Oct 28, 2024
- Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024, from 7:03AM ET on Monday Oct 28, 2024 by Dow Jones
  7:03AM ET on Monday Oct 28, 2024 by Dow Jones
  Companies Mentioned: UNCY
  
  Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. As part of the clinical development program, two clinical studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety and tolerability. The second study was a randomized, open-label, two-way crossover bioequivalence study to establish pharmacodynamic bioequivalence between OLC and Fosrenol. Based on the results of the bioequivalence study, pharmacodynamic (PD) bioequivalence of OLC to Fosrenol was established. A pivotal clinical trial was also conducted in CKD patients on hemodialysis that achieved the study objective and established favorable tolerability of OLC at clinically effective doses.

Nov 8, 2024
- DJ Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co., from 2:09PM ET on Friday Nov 08, 2024 by Dow Jones
  2:09PM ET on Friday Nov 08, 2024 by Dow Jones
  Companies Mentioned: BRNS
Nov 6, 2024
- Press Release: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: BRNS
- Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones
  Companies Mentioned: BRNS
Oct 31, 2024
- Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 -- The Liver Meeting(R) and Attendance at November Conferences, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 31, 2024 by Dow Jones
  Companies Mentioned: BRNS
Oct 24, 2024
- Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  8:00AM ET on Thursday Oct 24, 2024 by Dow Jones
  Companies Mentioned: PVCT

Unicycive Therapeutics Inc
NASDAQ:UNCYUnited States
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Search Criteria

Yesterday

DJ Unicycive Therapeutics Price Target Maintained With a $2.50/Share by HC Wainwright & Co., from 18 hours ago by Dow Jones

Nov 11, 2024

Unicycive Therapeutics Says FDA Accepts New Drug Application for Oxylanthanum Carbonate, from 7:47AM ET on Monday Nov 11, 2024 by MT Newswires

DJ Unicycive: FDA to Review Lead Drug Candidate for Hyperphosphatemia, from 7:31AM ET on Monday Nov 11, 2024 by Dow Jones

Unicycive Therapeutics Announces U.S. FDA Acceptance of the New Drug Application (NDA) for Oxylanthanum Carbonate (OLC) for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis, from 7:00AM ET on Monday Nov 11, 2024 by Dow Jones

Oct 28, 2024

Unicycive Therapeutics Delivers Multiple Poster Presentations Highlighting Development Progress on Oxylanthanum Carbonate (OLC) and UNI-494 at the American Society of Nephrology (ASN) Kidney Week 2024, from 7:03AM ET on Monday Oct 28, 2024 by Dow Jones

Peers Headlines

Nov 8, 2024

DJ Barinthus Biotherapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co., from 2:09PM ET on Friday Nov 08, 2024 by Dow Jones

Nov 6, 2024

Press Release: Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results, from 8:00AM ET on Wednesday Nov 06, 2024 by Dow Jones

Oct 31, 2024

Barinthus Bio Announces Late Breaking Presentation at AASLD 2024 -- The Liver Meeting(R) and Attendance at November Conferences, from 8:00AM ET on Thursday Oct 31, 2024 by Dow Jones

Oct 24, 2024

Provectus Biopharmaceuticals Announces Investor Webinar for Fourth Quarter 2024 Conference Call, from 8:00AM ET on Thursday Oct 24, 2024 by Dow Jones